Skip to main content

Table 2 (abstract A28). See text for description

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

Medication Number of patients newly starting at or after enrollment
Methotrexate 898
Leflunomide 168
Sulfasalazine 95
Adalimumab 711
Etanercept 668
Infliximab 160
Abatacept 129
Tocilizumab 174
Anakinra 53
Canakinumab 81
  1. Number of patients who newly started selected medications at or after enrollment (N=6,707)